Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.21.2
Consolidated Statements of Operations - USD ($)
12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]    
Collaboration revenue $ 483,626
Operating expenses:    
Research and development 16,634,553 9,877,555
Acquired in-process research and development 6,826,495
General and administrative 8,936,509 7,533,722
Total operating expenses 25,571,062 24,237,772
Loss from operations (25,087,436) (24,237,772)
Interest income 15 20,677
Foreign exchange loss (22,041) (48,020)
Other income 125,501
Net loss (24,983,961) (24,265,115)
Deemed dividend arising from warrant amendment (41,338,934)
Net loss attributable to common stockholders $ (24,983,961) $ (65,604,049)
Per share information:    
Net loss per share, basic and diluted $ (1.02) $ (6.96)
Weighted average shares outstanding, basic and diluted 24,547,290 9,420,484